2011
DOI: 10.1016/j.febslet.2011.03.019
|View full text |Cite
|
Sign up to set email alerts
|

Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein

Abstract: Edited by Noboru MizushimaKeywords: Cellular inhibitor of apoptosis protein 1 Cellular retinoic acid binding protein-II Protein knockdown Ubiquitin Proteasome a b s t r a c t Manipulation of protein stability with small molecules is a challenge in the field of drug discovery. Here we show that cellular retinoic acid binding protein-II (CRABP-II) can be specifically degraded by a novel compound, SNIPER-4, consisting of (À)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine methyl ester and all-trans retino… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
98
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 105 publications
(101 citation statements)
references
References 18 publications
3
98
0
Order By: Relevance
“…43 Furthermore, this hydroxyproline derivatives were further used for the synthesis of HaloPROTACs to target HaloTag7 fusion proteins, by developing chloroalkane-containing PROTACs against Halo Tag7 fusion protein using the acyl amine moiety for recognizing VHL. [53][54][55] They recruited a class of bestatin ester analogues (MeBS, methyl bestatin), a ligand binding to the baculoviral IAP repeat domains of cIAP1, to all-trans retinoid acid to target CRABP-I and II (cellular retinoic acid binding proteins-I and II). BRD4 inhibitors have been extendedly studied and shown promises in anticancer therapy against MYC-driven malignancies.…”
Section: Small Molecule-based Protacmentioning
confidence: 99%
See 1 more Smart Citation
“…43 Furthermore, this hydroxyproline derivatives were further used for the synthesis of HaloPROTACs to target HaloTag7 fusion proteins, by developing chloroalkane-containing PROTACs against Halo Tag7 fusion protein using the acyl amine moiety for recognizing VHL. [53][54][55] They recruited a class of bestatin ester analogues (MeBS, methyl bestatin), a ligand binding to the baculoviral IAP repeat domains of cIAP1, to all-trans retinoid acid to target CRABP-I and II (cellular retinoic acid binding proteins-I and II). BRD4 inhibitors have been extendedly studied and shown promises in anticancer therapy against MYC-driven malignancies.…”
Section: Small Molecule-based Protacmentioning
confidence: 99%
“…44 Many of the small molecule-based PROTACs have been developed intensively to target the BET family proteins. 55 Thus, the cIAP-1-based PROTAC could be able to induce the ubiquitination and degradation of the intracellular CRABP-I/II proteins. The first effort was to link BET inhibitor JQ1 to a moiety of VHL.…”
Section: Small Molecule-based Protacmentioning
confidence: 99%
“…5 Recently, the Hashimoto lab has successfully used bestatin to recruit cIAP1 to degrade CRABPs in cells. 14-17 However, bestatin is commonly used as an aminopeptidase inhibitor, which can lead to off-target effects. 18 Furthermore, ligands for IAPs often induce degradation of the E3 ligase itself, 19, 20 , (an effect observed with some bestatin hybrids) 16 that complicates their use in PROTACs.…”
Section: Introductionmentioning
confidence: 99%
“…2c), through the use of the ligand bestatin. cIAP1 based PROTACs have been used to selectively degrade a number of proteins, such as CRABP-II[25], ERα[26,27], and TACC3[28]. Unfortunately, these bestatin-based PROTACs, like the parent ligand[29], induced autoubiquitination and degradation of the E3 ligase itself, a potential explanation for their relatively low potency.…”
Section: Mdm2 and Iapmentioning
confidence: 99%